Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Physical inactivity has consistently been shown to be one of the most powerful, modifiable risk factors for all causes of death and disease, alongside smoking and obesity.
This interactive body map brings together scientific evidence on the links between lack of physical activity and disease.
Click on the coloured dots on the body, or choose a specific disease from the dropdown menu, or cycle through all diseases via the next and previous buttons.
To use the map, click on any of the coloured dots on the body, or choose a specific disease from the dropdown menu. You can also filter by disease or condition type.
This is the first in our package on the benefits of exercise. Read other articles in the package here.
For a copy of the data and notes on the methodology used for the calculations, please visit The Conversation’s GitHub page.
Carol Maher receives funding from the National Health and Medical Research Council and the National Heart Foundation.
Tim Olds receives funding from the ARC and the NHMRC.
This article was originally published on The Conversation. Read the original article.
